-
Cambrex Buys Avista for $252M
contractpharma
November 27, 2018
Cambrex has entered into a definitive agreement to acquire Avista Pharma Solutions for roughly $252 million. Avista is a portfolio company of Ampersand Capital Partners.
-
ASIT Biotech Adds GMP Manufacturing Unit
contractpharma
November 27, 2018
ASIT biotech has installed and qualified a clean room with the equipment to produce, in compliance with GMP requirements, the API for the Phase I/II studies in house dust mite and peanut allergies treatment.
-
Acquisition boosts Cambrex's early-stage development capabilities
cphi-online
November 27, 2018
Avista is a portfolio company of Ampersand Capital Partners, a leading healthcare-focused private equity firm. With this acquisition, Cambrex will enter the large and growing market
-
Piramal Pharma Solutions unveils cGMP kilo lab suite for API
expressbpd
November 22, 2018
The suite in Chennai will formally open on December 1, 2018
-
Bedrocan becomes world’s first GMP cannabis producer
cphi-online
November 15, 2018
Following a rigorous inspection by the Dutch Health Care Inspectorate, Bedrocan in the Netherlands has become the world’s first producer of medicinal cannabis to be compliant...
-
GlaxoSmithKline expands API production for COPD inhalers as Advair sales wither
fiercepharma
October 24, 2018
Even with looming generic competition expected to take a big bite out of sales of its blockbuster Advair, respiratory drugs remain key to GlaxoSmithKline, and it continues to plow money into their production.
-
WuXi's API manufacturing passes FDA inspection
biospectrumasia
October 23, 2018
WuXiPharmaTech passed inspection for API manufacturing baseSingapore:China-based WuXiPharmaTech, pharmaceutical, biotech
-
Govt aims to raise API production to cut Chinese dependence
expressbpd
October 11, 2018
The government is working on a road map to increase production of bulk drugs in the country with a view to reduce import
-
Litigation teaches Chinese valsartan maker the downside of U.S. market
fiercepharma
October 10, 2018
China’s Zhejiang Huahai Pharmaceutical for years enjoyed the upside of the U.S. pharmaceutical market, selling its valsartan API to drugmakers producing blood pressure meds for the market.
-
EU regulators blast China’s Zhejiang Huahai over valsartan API mess
fiercepharma
September 29, 2018
The European Medicines Agency has piled onto China’s Zhejiang Huahai, finding its manufacturing out of compliance for the valsartan API that has been recalled globally after being found to contain a suspected carcinogen.